Christopher T. Chen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Pharmacologic restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma. However, the p53 pathway has remained undruggable, partly because of insufficient understanding of how to drive effective therapeutic responses without toxicity. In this study, we use mouse and human models to deconstruct the transcriptional programs and sequelae underlying robust therapeutic responses in lung adenocarcinoma. We show that p53 drives potent tumor regression by direct Tsc2 transactivation, leading to mTORC1 inhibition and Transcription factor EB (TFEB) nuclear accumulation, which in turn triggers lysosomal gene expression programs, autophagy, and cellular senescence. Senescent lung adenocarcinoma cells secrete factors to recruit macrophages, precipitating cancer cell phagocytosis and tumor regression. Collectively, our analyses reveal a surprisingly complex cascade of events underlying a p53 therapeutic response in lung adenocarcinoma and illuminate targetable nodes for p53 combination therapies, thus establishing a critical framework for optimizing p53-based therapeutics. Significance: Cancer therapies based on targeting the p53 pathway remain elusive. To address this gap, we unravel the detailed sequence of events governing p53-induced tumor regression in lung adenocarcinoma. These analyses reveal a TSC2–mTORC1–TFEB axis underlying p53-driven senescence and tumor regression, which suggests new strategies to perfect p53-based combination therapies for lung adenocarcinoma.
Year:
2026
Pharmacologic restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma. However, the p53 pathway has remained undruggable, partly because of insufficient understanding of how to drive effective therapeutic responses without toxicity. In this study, we use mouse and human models to deconstruct the transcriptional programs and sequelae underlying robust therapeutic responses in lung adenocarcinoma. We show that p53 drives potent tumor regression by direct Tsc2 transactivation, leading to mTORC1 inhibition and Transcription factor EB (TFEB) nuclear accumulation, which in turn triggers lysosomal gene expression programs, autophagy, and cellular senescence. Senescent lung adenocarcinoma cells secrete factors to recruit macrophages, precipitating cancer cell phagocytosis and tumor regression. Collectively, our analyses reveal a surprisingly complex cascade of events underlying a p53 therapeutic response in lung adenocarcinoma and illuminate targetable nodes for p53 combination therapies, thus establishing a critical framework for optimizing p53-based therapeutics. Significance: Cancer therapies based on targeting the p53 pathway remain elusive. To address this gap, we unravel the detailed sequence of events governing p53-induced tumor regression in lung adenocarcinoma. These analyses reveal a TSC2–mTORC1–TFEB axis underlying p53-driven senescence and tumor regression, which suggests new strategies to perfect p53-based combination therapies for lung adenocarcinoma.
Year:
2025
Study disposition flow diagram of patient disposition. Note: int, intermittent regimen of ORIC-101 administered 5 days on, 2 days off for 21 days out of 28-day cycles; cont, continuous regimen of ORIC-101 administered for 21 days out of 28-day cycles; AE, adverse event; clin, clinical; OST, other solid tumors; PD, progressive disease; radiog, radiographic.
Year:
2025
ORIC-101 pharmacodynamics in PBMCs and tumor specimens. A, Pharmacodynamic (PD) modulation (average expression of GR target genes FKBP5 , GILZ , and PER1 ) on day 1 of cycle 1 as observed in 40 dose expansion patients with PBMC sample collection and cortisol assessment at C1D1 (pre-dose and 6 hours post-dose), and with pre-dose cortisol levels >200 nmol/L. Samples are colored by cohort. B, PD suppression from cycle 1 day 1 (pre-dose) to day 15 (pre-dose) as observed in 26 patients with PBMC sample collection and cortisol assessment at C1D1 pre-dose and C1D15 pre-dose, and with C1D1 pre-dose cortisol levels >200 nmol/L. C, PD suppression from cycle 1 day 1 (pre-dose) to cycle 2 day 1 (pre-dose) as observed in 28 patients with PBMC sample collection and cortisol assessment at C1D1 pre-dose and C2D1 pre-dose, and with C1D1 pre-dose cortisol levels >200 nmol/L. D, PD modulation on day 1 of cycle 2 as observed in 30 dose expansion patients with PBMC sample collection and cortisol assessment at C2D1 (pre-dose and 6 hours post-dose) and with pre-dose cortisol levels >200 nmol/L. E, On-treatment change in GR activation signaling in 10 patients (four dose escalation, six dose expansion) with paired tumor biopsies. The horizontal arrows indicate directionality of observed changes in GR activation as indicated by GR Signature Score (average expression of FKBP5 , GILZ , PER1 , and KLF9 ) from screening to end of cycle 2 or end of treatment, in the 10 patients. The solid line shows the expected distribution of GR activation from a reference cohort of archival and fresh tumor biopsies collected during this ORIC-101 trial. Patients with decreased GR signaling are highlighted in the boxed area. F, Association of on-treatment decrease in GR activation signaling with longer time on treatment.
Year:
2025
GR antagonism by ORIC-101 overcomes taxane resistance in preclinical models. A and B, Effect of ORIC-101 on dexamethasone-induced chemoprotection in vitro as measured by ( A ) caspase 3/7 apoptosis assays and ( B ) colony formation assays, in three TNBC lines (HCC1806, MDA-MB-231, Hs578T), three PDAC lines (BxPC3, SW1990, PSN1), and ovarian cancer line COV362. Veh: vehicle; Dex: 30 nmol/L dexamethasone; 101: 0.5 μmol/L ORIC-101; Chemo = 100 nmol/L paclitaxel + 100 nmol/L gemcitabine; PTX = 100 nmol/L paclitaxel; DTX = 100 nmol/L docetaxel; Gem = 100 nmol/L gemcitabine. A, The caspase activities of Veh were assigned as 1, and the values for other conditions were relative to Veh. One representative experiment with three biological repeats is shown (mean ± SEM). *, P P P B, One representative experiment with three biological repeats is shown. Numbers in white indicate the percentage of confluency quantitated by Celigo S. C, Effect of ORIC-101 on paclitaxel response in taxane-naïve HCC1806 TNBC xenografts in cortisol-treated mice. Mice were treated with paclitaxel 20 mg/kg by intraperitoneal injection every 3 days for a total of eight cycles (20 mg/kg, IP, Q3D × 8), cortisol (100 mg/L in drinking water, ad libitum ) or ORIC-101 75 mg/kg by oral administration twice daily (75 mg/kg, PO, BID) starting on day 0 for the duration of the study. Arrowheads indicate PTX dosing days. Data are displayed as mean ± SEM. D and E, Effect of ORIC-101 in paclitaxel-relapsed HCC1806 TNBC xenografts in cortisol-treated mice. D, Animals were dosed with paclitaxel (15 mg/kg, IP, Q3Dx5) as indicated by the black arrowheads or ORIC-101 (150 mg/kg, PO, QD) as indicated by gray line. n = 15 in each group. Data is displayed as mean ± SEM. E, PFS, defined as the time elapsed between treatment initiation of the second cycle of paclitaxel and tumor progression or death from any cause, as a percentage of all animals in each cohort. A Kaplan–Meier plot was constructed to show the percentage of animals remaining in the study following treatment ( P F, Overall survival, defined as the time elapsed between treatment initiation of the second cycle of paclitaxel and death from any cause as a percentage of all animals in each cohort, was not significantly different between the cohorts (by log-rank test).
Year:
2024
GR antagonism by ORIC-101 overcomes taxane resistance in preclinical models. A and B, Effect of ORIC-101 on dexamethasone-induced chemoprotection in vitro as measured by ( A ) caspase 3/7 apoptosis assays and ( B ) colony formation assays, in three TNBC lines (HCC1806, MDA-MB-231, Hs578T), three PDAC lines (BxPC3, SW1990, PSN1), and ovarian cancer line COV362. Veh: vehicle; Dex: 30 nmol/L dexamethasone; 101: 0.5 μmol/L ORIC-101; Chemo = 100 nmol/L paclitaxel + 100 nmol/L gemcitabine; PTX = 100 nmol/L paclitaxel; DTX = 100 nmol/L docetaxel; Gem = 100 nmol/L gemcitabine. A, The caspase activities of Veh were assigned as 1, and the values for other conditions were relative to Veh. One representative experiment with three biological repeats is shown (mean ± SEM). *, P P P B, One representative experiment with three biological repeats is shown. Numbers in white indicate the percentage of confluency quantitated by Celigo S. C, Effect of ORIC-101 on paclitaxel response in taxane-naïve HCC1806 TNBC xenografts in cortisol-treated mice. Mice were treated with paclitaxel 20 mg/kg by intraperitoneal injection every 3 days for a total of eight cycles (20 mg/kg, IP, Q3D × 8), cortisol (100 mg/L in drinking water, ad libitum ) or ORIC-101 75 mg/kg by oral administration twice daily (75 mg/kg, PO, BID) starting on day 0 for the duration of the study. Arrowheads indicate PTX dosing days. Data are displayed as mean ± SEM. D and E, Effect of ORIC-101 in paclitaxel-relapsed HCC1806 TNBC xenografts in cortisol-treated mice. D, Animals were dosed with paclitaxel (15 mg/kg, IP, Q3Dx5) as indicated by the black arrowheads or ORIC-101 (150 mg/kg, PO, QD) as indicated by gray line. n = 15 in each group. Data is displayed as mean ± SEM. E, PFS, defined as the time elapsed between treatment initiation of the second cycle of paclitaxel and tumor progression or death from any cause, as a percentage of all animals in each cohort. A Kaplan–Meier plot was constructed to show the percentage of animals remaining in the study following treatment ( P F, Overall survival, defined as the time elapsed between treatment initiation of the second cycle of paclitaxel and death from any cause as a percentage of all animals in each cohort, was not significantly different between the cohorts (by log-rank test).
Year:
2024
ORIC-101 pharmacodynamics in PBMCs and tumor specimens. A, Pharmacodynamic (PD) modulation (average expression of GR target genes FKBP5 , GILZ , and PER1 ) on day 1 of cycle 1 as observed in 40 dose expansion patients with PBMC sample collection and cortisol assessment at C1D1 (pre-dose and 6 hours post-dose), and with pre-dose cortisol levels >200 nmol/L. Samples are colored by cohort. B, PD suppression from cycle 1 day 1 (pre-dose) to day 15 (pre-dose) as observed in 26 patients with PBMC sample collection and cortisol assessment at C1D1 pre-dose and C1D15 pre-dose, and with C1D1 pre-dose cortisol levels >200 nmol/L. C, PD suppression from cycle 1 day 1 (pre-dose) to cycle 2 day 1 (pre-dose) as observed in 28 patients with PBMC sample collection and cortisol assessment at C1D1 pre-dose and C2D1 pre-dose, and with C1D1 pre-dose cortisol levels >200 nmol/L. D, PD modulation on day 1 of cycle 2 as observed in 30 dose expansion patients with PBMC sample collection and cortisol assessment at C2D1 (pre-dose and 6 hours post-dose) and with pre-dose cortisol levels >200 nmol/L. E, On-treatment change in GR activation signaling in 10 patients (four dose escalation, six dose expansion) with paired tumor biopsies. The horizontal arrows indicate directionality of observed changes in GR activation as indicated by GR Signature Score (average expression of FKBP5 , GILZ , PER1 , and KLF9 ) from screening to end of cycle 2 or end of treatment, in the 10 patients. The solid line shows the expected distribution of GR activation from a reference cohort of archival and fresh tumor biopsies collected during this ORIC-101 trial. Patients with decreased GR signaling are highlighted in the boxed area. F, Association of on-treatment decrease in GR activation signaling with longer time on treatment.
Year:
2024
Purpose: In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist that was investigated in combination with taxane chemotherapy as an anticancer regimen preclinically and in a phase 1 clinical trial. Patients and Methods: The ability of ORIC-101 to reverse taxane resistance was assessed in cell lines and xenograft models, and a phase 1 study (NCT03928314) was conducted in patients with advanced solid tumors to determine the dose, safety, and antitumor activity of ORIC-101 with nab-paclitaxel. Results: ORIC-101 reversed chemoprotection induced by glucocorticoids in vitro and achieved tumor regressions when combined with paclitaxel in both taxane-naïve and -resistant xenograft models. In the phase 1 study, 21 patients were treated in dose escalation and 62 patients were treated in dose expansion. All patients in dose expansion had previously progressed on a taxane-based regimen. In dose escalation, five objective responses were observed. A preplanned futility analysis in dose expansion showed a 3.2% (95% confidence interval, 0.4–11.2) objective response rate with a median progression-free survival of 2 months (95% confidence interval, 1.8–2.8) across all four cohorts, leading to study termination. Pharmacodynamic analysis of tissue and plasma showed GR pathway downregulation in most patients in cycle 1. Conclusions: ORIC-101 with nab-paclitaxel showed limited clinical activity in taxane-resistant solid tumors. Despite clear inhibition of GR pathway signaling, the insufficient clinical signal underscores the challenges of targeting a single resistance pathway when multiple mechanisms of resistance may be in play. Significance: Glucocorticoid receptor (GR) upregulation is a mechanism of resistance to taxane chemotherapy in preclinical cancer models. ORIC-101 is a small molecule GR inhibitor. In this phase 1 study, ORIC-101 plus nab-paclitaxel did not show meaningful clinical benefit in patients who previously progressed on taxanes despite successful GR pathway downregulation.
Year:
2024
Study disposition flow diagram of patient disposition. Note: int, intermittent regimen of ORIC-101 administered 5 days on, 2 days off for 21 days out of 28-day cycles; cont, continuous regimen of ORIC-101 administered for 21 days out of 28-day cycles; AE, adverse event; clin, clinical; OST, other solid tumors; PD, progressive disease; radiog, radiographic.
Year:
2024
Purpose: In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist that was investigated in combination with taxane chemotherapy as an anticancer regimen preclinically and in a phase 1 clinical trial. Patients and Methods: The ability of ORIC-101 to reverse taxane resistance was assessed in cell lines and xenograft models, and a phase 1 study (NCT03928314) was conducted in patients with advanced solid tumors to determine the dose, safety, and antitumor activity of ORIC-101 with nab-paclitaxel. Results: ORIC-101 reversed chemoprotection induced by glucocorticoids in vitro and achieved tumor regressions when combined with paclitaxel in both taxane-naïve and -resistant xenograft models. In the phase 1 study, 21 patients were treated in dose escalation and 62 patients were treated in dose expansion. All patients in dose expansion had previously progressed on a taxane-based regimen. In dose escalation, five objective responses were observed. A preplanned futility analysis in dose expansion showed a 3.2% (95% confidence interval, 0.4–11.2) objective response rate with a median progression-free survival of 2 months (95% confidence interval, 1.8–2.8) across all four cohorts, leading to study termination. Pharmacodynamic analysis of tissue and plasma showed GR pathway downregulation in most patients in cycle 1. Conclusions: ORIC-101 with nab-paclitaxel showed limited clinical activity in taxane-resistant solid tumors. Despite clear inhibition of GR pathway signaling, the insufficient clinical signal underscores the challenges of targeting a single resistance pathway when multiple mechanisms of resistance may be in play. Significance: Glucocorticoid receptor (GR) upregulation is a mechanism of resistance to taxane chemotherapy in preclinical cancer models. ORIC-101 is a small molecule GR inhibitor. In this phase 1 study, ORIC-101 plus nab-paclitaxel did not show meaningful clinical benefit in patients who previously progressed on taxanes despite successful GR pathway downregulation.
Year:
2024
Year:
2024
Year:
2023
Collaborators (6)
Shivaani Kummar
Oregon Health & Science University
Naoto Ueno
Professor of Medicine
University of Hawai'i Cancer Center
Samer Al Hadidi
Associate Professor , Clinical Director of Amyloidosis Program
University of Texas Southwestern Medical Center
Vaia Florou
Associate Professor
Huntsman Cancer Institute
Elsa Flores
Associate Center Director, Basic Science
H Lee Moffitt Cancer Center and Research Institute
Pamela N. Munster
Professor
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.